Sane, F, Bertin, A, Sioofy‐Khojine, A‐B, et al. Enhancing and neutralizing anti‐coxsackievirus activities in serum samples from patients prior to development of type 1 diabetes. Diabetes Metab Res Rev. 2020; 36:e3305. https://doi.org/10.1002/dmrr.3305
Enhancing and neutralizing anti‐coxsackievirus activities in serum samples from patients prior to development of type 1 diabetes
|Author:||Sane, Famara1; Bertin, Antoine1; Sioofy-Khojine, Amir-Babak2;|
1Univ Lille, Faculté de Médecine, CHU Lille, Laboratoire de virologie EA3610, 59000 Lille, France
2Department of Virology, Faculty of Medicine and Health Technology, Tampere University, FI-33520, Tampere, Finland
3Department of Paediatrics, PEDEGO Research Unit, Medical Research Centre, Oulu University Hospital and University of Oulu, Oulu, Finland
4Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku; Dept. of Pediatrics, Turku University Hospital, Turku, Finland
5Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland
6Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
8Tampere Centre for Child Health Research, Tampere University Hospital, Tampere, Finland
9Folkhälsan Research Centre, Helsinki, Finland
10Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020101584120
John Wiley & Sons,
|Publish Date:|| 2021-03-02
Background: Studies in prospective cohorts have suggested that enterovirus infections are associated with the appearance of islet autoantibodies that precede later appearance of type 1 diabetes (T1D). It was shown that in addition to an antibody‐mediated anti‐coxsackievirus (CV)‐B neutralizing activity of serum from patients with T1D, there was also enhancing anti‐CV‐B activity in vitro. In this study, the patterns of enhancing and neutralizing anti‐CV activities were analysed from consecutive serum samples collected from children who were followed from birth until they developed T1D in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study and compared to those in non‐diabetic control children.
Methods: The titres of serum neutralizing activity were analysed against those CVs which were detected in the stools in these children (CV‐B3, CV‐B5 or CV‐A4) using plaque assay. The enhancing activity of these serum samples was analysed by measuring interferon‐alpha (INF‐α) production in cultures of peripheral blood mononuclear cells (PBMC) inoculated with a mixture of these viruses and diluted serum.
Results: A sustained anti‐CV enhancing activity was observed in consecutive serum samples in patients with T1D. The pattern of responses differed between children who developed T1D and control children. In patients, the anti‐CV enhancing activity was predominant or even exclusive over the neutralizing activity, whereas in controls the enhancing and neutralising activities were more balanced or the neutralizing activity was largely predominant.
Conclusions: Evaluating the anti‐enterovirus neutralizing and enhancing activity of serum samples can be useful to investigate further the relationship between enteroviruses and the development of T1D.
Diabetes/metabolism research and reviews
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3121 General medicine, internal medicine and other clinical medicine
This work was supported by Ministère de l'Education Nationale de la Recherche et de la Technologie, Université Lille (Equipe d'accueil 3610) and Centre Hospitalier et Universitaire de Lille, by EU FP7 (GA‐261441‐PEVNET: Persistent virus infection as a cause of pathogenic inflammation in type 1 diabetes—an innovative research program of biobanks and expertise) and by Reino Lahtikari Foundation.
© 2020 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Sane, F, Bertin, A, Sioofy‐Khojine, A‐B, et al. Enhancing and neutralizing anti‐coxsackievirus activities in serum samples from patients prior to development of type 1 diabetes. Diabetes Metab Res Rev. 2020; 36:e3305, which has been published in final form at https://doi.org/10.1002/dmrr.3305.
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.